Due to complexities and genetic heterogeneities of biological phenotypes, robust computational approaches are desirable to achieve high generalization performance with multiple classifiers, perturbations of the data structures, and biological interpretations. The purpose of this study is to extend our developed ensemble decision approach to distinguish multiple heterogeneous phenotypes and to elucidate the underlying molecular bridges that intertwine the subtypes. Our work identifies the significant molecular mechanisms (disease-relevant genes and functions) that underpin the complex molecular mechanisms for distinction between multiple phenotypes. Feature genes and hierarchical gene cores identified by our method have achieved high accuracy in the classification of multiple phenotypes. The results show that the proposed analysis strategy is feasible and powerful in the classification of biological subtypes and in the explanation of the molecular connections between clinical phenotypes. Biological interpretations with Gene Ontology revealed concerted genetic pathways for some lymphoma subtypes.
Introduction
Complex diseases are the result of the collective actions of many genetic and non-genetic factors; therefore, the genetic dissection of complex diseases should be carried out by a new systematic technology. Gene expression microarray is an efficient and high throughout method for genetically profiling diseases and their associated treatments. Such a process involves a key step of biomarker identification, which is expected to be closely related to the disease. A most important task of these identified genes is that they can be used to construct a classifier which can effectively diagnose diseases and even recognize the disease subtypes. Binary classification, for example, for the diseased or healthy, in microarray data analysis has been successful; while multi-class classification, such as cancer subtyping, remains challenging. The patterns of up-regulation or down-regulation of gene activities can serve as secondary endpoints of biomarkers [1] , and the method of finding such biomarkers is actually the application of traditional feature selection methods in the field of molec-ular biology and life sciences. Feature selection aims to pick out d features from D features (D > d) that can best discriminate between heterogeneous samples [2] .
Traditional feature selection methods are devoted to producing a small set of biomarker genes which can be used in classifier construction such as linear discrimination analysis, nearest neighbor models, support vector machines, and logistic regression models [3] [4] [5] . These gene selection methods typically find the best feature subset; however, researchers cannot always get a good classifying performance and biological comprehension because such feature selection methods focus on finding the best feature subset which contains a few genes and which is also sensitive to many factors such as learning algorithms and training samples.
It is important to point out that most of these gene selection methods and the associated classifiers are usually worked on two-class datasets, though they can be theoretically extended to multi-class datasets through one-versusall (OVA). The methods have been tested on multi-class dataset(s) [3, 4] .
Using ensembles of base classifiers to improve classifying performance has been a hot topic of machine learning [6] . While binary classification has been extensively explored, multi-class classification remains challenging in microarray data analysis. In this work, we focus on gene selection for multi-class classification and we demonstrate the power of the proposed method by applying it to the identification of a cancer subtype. We have extended our newly developed ensemble decision approach [7] to the analysis of multiple heterogeneous phenotypes and to elucidate the underlying molecular mechanisms that intertwine the phenotypes. Rather than simply maximizing prediction accuracy, we further identify the genes that are most relevant to a disease by retrieving 'redundant' genes which are excluded during the course of feature selection but actually are strongly relevant to the disease. Besides analyzing the role of key genes, we also unravel the molecular mechanisms of multiple phenotypes at the function level by mapping genes onto Gene Ontology [8] [9] [10] .
Methods

Ensemble of feature selection
The whole process of ensemble of feature selection is simply depicted in Fig. 1 and described as follows.
The feature genes of the numerous subtypes of the lymphoma datasets are heterogeneous in feature space, which shows that individual genes are of unequal importance in different regions of the whole feature space. In our work, a multi-class problem is firstly transformed into a two-class (the positive and the negative) problem, more specifically, the positive samples are gathered from the samples of a certain lymphoma subtype, while the negative samples are collected randomly from the other lymphoma subtypes. The training sets and the test sets are achieved by boosting and randomly grouping the positive and the negative samples. Sets of original feature subsets are acquired by decision tree method, each feature subset G c j (c = 1, 2, . . ., C, Fig. 1 . Ensembles of feature selection of multiple phenotypes based on 4026 genes. j = 1, 2, . . ., kc) includes the split nodes and split rule in one decision tree, and can discriminate samples of the positive and the negative, where C denotes the number of subtypes, and j denotes the serial number of a feature subset. In this paper, we do not differentiate between feature subsets and decision trees clearly, that is, one decision tree corresponds to one feature subset. C original feature subsets constitute the original forest.
Then the feature subset with d > 0.6 is picked out as 'fine subset' G c j (c = 1, 2, . . ., C, j = 1, 2, . . ., kc 0 ).
where d is the classifying performance of each feature subset G c j under supervised learning, while p = TP/(FP + TP), r = TP/(FN + TP), TP is true positive, FP is false positive, TN is true negative, and FN is false negative. The d is high if both false positive (FP) and false negative (FN) are low. Consequently, C fine feature subsets constitute the fine forest.
The next step is to ensemble feature genes. Genes with the high appearance frequency in the fine feature subsets are recognized as feature genes because they do not depend on the composition of training samples. The algorithm which we developed on the basis of algorithm Mining Core [11] is applied to determine gene cores in which high-frequency genes are grouped together. The inputs of this algorithm are the set of fine feature subsets, if there are genes shared by at least 2 feature subsets, these genes constitute one gene core. Moreover, we take gene cores found above as the input of the algorithm, thereby, the output is a group of hierarchical gene cores Core Feature genes and gene cores are selected by the method of ensemble of the feature selections, but there are still some genes that are never selected because of their redundancy relative to the selected genes, namely their expression profiles are similar to those of selected genes. However, genes with similar expression profiles are inclined to be in the same metabolic pathway, same signal transduction pathway or be in the different components of a protein complex [12] [13] [14] . Without these redundant genes it would be difficult to understand the whole process of changes of a disease at the molecular level. Thus, we delete selected genes and perform the previous work repeatedly to retrieve more genes until the classifying performance no longer falls in five consecutive repeats.
Moreover, feature genes selected by a decision tree may not be up-regulated or down-regulated in the samples of a certain lymphoma subtype. So we further filter genes of normal versus lymphoma subtypes by Student's t-test [15] .
Biological evaluation of feature genes
Based on gene ID and three other databases, GenBank [16] , Unigene [17, 18] and LocusLink [19] , feature genes are mapped into Gene Ontology (GO). Fisher test [15] is applied to get function terms in GO with significance level of 0.05. The feature genes enriched in the function terms are partly selected for biological evaluation. The function terms belonging to different lymphoma subtypes can help us understand the relationship between the disease and function.
Results
Lymphoma dataset
The lymphoma expression profile dataset we have used [20, 21] includes 86 samples of five classes and 4026 genes: 21 GCB-like-DLBCL samples (germinal centre B-like DLBCL) (class 1), 21 AB-like-DLBCL samples (activated B-like DLBCL) (class 2); 11 CLL samples (chronic lymphocytic leukaemia) (class 3); 9 FL samples (follicular lymphoma) (class 4) and 24 normal samples (class 5). Samples in different normal classes were merged into one class for their small sample numbers, and samples without Table 1 The step-by-step algorithm of ensemble of the feature selection
Step 1. Randomly split all samples into two parts. One part (1/5) is the validation set which never takes part in feature selection process.
Step 2. The other part (4/5) is randomly divided into training set and testing set. Threefold cross-validation technology is used.
Step 3. Samples are transformed into those with the two-class label.
Boosting builds a series of feature subsets belonging to each class while training set is fixed.
Step 4. Pick out fine feature subsets belonging to each class under the direction of testing set's classifying performance (d > 0.6).
Step 5. Repeat Step 2 to Step 4 twenty times to achieve a series of fine feature subsets belonging to each class fG
Step 6. Repeat Step 1 to Step 5 ten times.
Step 7. Achieve ten series of fG
Step 1 to Step 6. Calculate frequency of each gene in each series of fG
g and pick out genes with frequency f P 2 to enter feature genes set {F c }. Then we calculate the accumulative frequency of genes which appeared in ten series of {F c } and pick out genes with a frequency higher than nine times to enter final feature genes set {fF c }.
Step 8. Mine hierarchical gene cores.
Step 9. Classifying performance evaluation using the validation set.
Step 10. Delete selected genes and repeat the previous work again and again to retrieve more genes and add to {fF c }.
Step 11. Biological evaluation of feature genes in the set {fF c } and gene cores. Normal Gene core 1 56 GENE1836X Unknown UG Hs.190487 ESTs; Clone = 1358277 GENE3795X AIM2 = interferon-inducible protein = associated with chromosome 6-mediated suppression of melanoma Gene core 2 51 GENE3073X SEC14-like; Clone = 685336 GENE3795X AIM2 = interferon-inducible protein = associated with chromosome 6-mediated suppression of melanoma Gene core 3 36 GENE1835X Unknown; Clone = 1357915 GENE3795X AIM2 = interferon-inducible protein = associated with chromosome 6-mediated suppression of melanoma a typical expression profile were deleted. Most of the cDNA clones on the microarray were chosen from a germinal centre B-cell library because of the suspected importance of the germinal centre B-cell to the genesis of nonHodgkin's lymphomas.
Experiment
The whole work is summarized in Table 1 . All algorithms in this paper are achieved using MATLAB 6.5 and JAVA 1.4. The retrieval process of the redundant genes is described in Fig. 2 . In this figure, classifying performance falls when feature genes are deleted, and this retrieval process stops at the point where the accuracy has no apparent decline in the consecutive five repeating process. We retrieved the deleted genes before the point where these genes become important for classifying and biological interpretations.
Establishing molecular mechanisms of lymphoma subtypes
The target phenotypes are multiple subtypes of lymphoma. Thus, our work is conducted to identify the significant molecular mechanisms (disease-relevant genes and functions) that underpin the complex molecular mechanisms for the distinction of multiple phenotypes. Gene cores of multiple phenotypes are shown in Table 2 . Although many of the genes lack the function annotation, these genes are worthy of further investigation.
Still some other core genes are intriguing: Osteoblastspecific factor (OSF-2os), a putative bone adhesion protein with homology in insects and named GENE1639X, is a key gene of five gene cores that are strongly related to AB-like-DLBCL samples and over-expressed in them. Gui et al. [22] developed a threshold gradient descent method for the Cox model to select genes that are relevant to DLBCL patients' survival. An osteoblast-specific factor is included in the genes that were identified to be related to the risk of death, which belongs to the lymph node signature defined by Rosenwald et al. [23] using clustering analysis of genes. Osteoblast-specific factor-2 has been described as a transcription factor of osteopontin (OPN), the protein associated with the progression and metastasis formation of various cancer types. Our work confirmed that OSF-2os is over-expressed in AB-like-DLBCL samples, and this finding might well be used for an understanding of the progression and metastasis of AB-like-DLBCL.
GENE2395X is a strongly relevant gene for the distinction of CLL samples from other samples and appears in three gene cores. Moreover, GENE2395X is mapped in MAPK signaling pathway in KEGG database. Another gene, GENE1141X, mitogen-activated kinase kinase kinase 5, is also relevant to CLL samples. This implies that the MAPK signaling pathway is affected in CLL development and progression, and both GENE2395X and GENE1141X play the key role in this pathway. More evidence described in the next text confirms that the MAPK signaling pathway is activated abnormally. Another core gene, Titin, was reported to be over-expressed in CLL samples [23] .
BCL-2 gene in the set {fF 3 } associated with CLL samples is strongly over-expressed. Multiple lines of evidence from molecular biological studies imply that the over-expression of this gene occurs in many forms of leukaemia, and so contributes to the relentless accumulation of lymphocytes that fail to die and to their resistance to chemotherapy. But in our signature, over-expression of BCL-2 is only typical in CLL samples. High expression of the antiapoptotic protein BCL-2, a profound inhibitor of programmed cell death, has been reported in the vast majority of B-cell CLLs [24] [25] [26] . Fegan's research [27] has shown that BCL-2 protein is one of the several proteins that regulate cell death. BCL-2 protein inhibits programmed cell death and is consistently over-expressed in B-CLL patients. Over-expression of BCL-2 is present in over 90% of B-CLL patients.
For AB-like-DLBCL and GCB-like-DLBCL, it is hard to capture more information on the molecular links. The main causes are that some feature genes are lacking in function annotation and the significant function concepts of GO mapped by remnant feature genes are not specific enough to explain anything.
For FL and CLL, We further analyzed function concepts mapped by these relevant genes to understand the disease mechanism at the functional level.
The function concepts mapped by feature genes of CLL are listed in Table 3 . There are some function concepts such as 'MAPKKK cascade', 'MAP kinase kinase kinase', 'protein tyrosine kinase', 'protein tyrosine phosphatase', 'activation of JUN kinase' and 'small GTPase-mediated signal transduction' to be selected. There are published papers reporting that JUN kinase activation has been implicated as a major player in the induction of apoptosis by a number of agents and has also recently been shown to result in p53 activation and subsequent p53-mediated apoptosis in sympathetic neurons [28, 29] . These function concepts indicate that two pathways of cellular signal transduction, tyrosine protein kinase-mitogen activated protein kinase pathway (TPK-MAPK) and small GTPase-mediated signal transduction pathway, are both activated abnormally, which brings on an excessive proliferation of tumor cells. Genes mapped onto function concepts MAPKKK cascade, MAP kinase, protein tyrosine kinase and activation of JUN kinase are up-regulated entirely, which means that the TPK-MAPK signal transduction pathway is activated abnormally and persistently.
From the information listed in Table 3 , we surmise that one of the earlier processes is the activation of the protein tyrosine kinases (JAK2 tyrosine kinase, SKAP55, lyn, FGR tyrosine kinase), which results in the activation of MAPK cascade (MAPKKK, unknown clone = 1369098). Some researchers report that Protein kinase A (PKA) and mitogen-activated protein kinases (MAPKs) have been involved in the apoptosis of B-CLL cells [30, 31] . However, all the genes associated with protein tyrosine phosphatase are also up-regulated. It is possible that the level of protein tyrosine phosphatase is correspondingly up-regulated in order to keep a low level of tyrosine phosphorylation, while the expression level of tyrosine kinase is up-regulated. In addition, genes linked to another signal transduction pathway, a small GTPase-mediated signal transduction, are also over-expressed entirely. This means such a pathway is also activated, but now we fail to find any related research to confirm it. Significant function concepts we have found confirm such a theory further [32] that the occurrence of a tumor has a close relationship with signal transduction. The function concepts mapped by feature genes of FL are listed in Table 4 . Some function concepts such as 'transcription factor', 'transcription co-activator' and 'transcription co-repressor' are selected. Genes mapped onto 'transcription factor' and 'transcription co-activator' are over-expressed and 'transcription co-repressor' are downexpressed, which is consistent with tumor pathogenesis. 'Adenosinetriphosphatase', 'calcium-transporting ATPase', 'protein tyrosine phosphatase' and 'inositol-1,4,5-trisphosphate' function concepts are also selected, and genes mapped onto them are over-expressed; however, presently no evidence supports the relationship of these function concepts with FL.
To investigate whether the genes in the molecular mechanisms can classify these subtypes of lymphoma well, we use the Two-Level Integrating Evaluation Machine [7] to assess the classifying performance (accuracy) of the fine forest and hierarchical core forest and to compare it with the original forest when ten series of validation sets are fixed. Results in Fig. 3 show that the average accuracy of fine forest reaches 86.50%, which is remarkably higher than that of original forest (54.32%). Such a classifying performance is also high compared with that of other classifying algorithms for multi-class samples [6] . Moreover, accuracy of deeper-level core forest does not noticeably reduce along with the decrease of the number of genes in core forest.
In the feature selection approach, we performed external cross-validation [7] , then with a validation set and separate classifiers we carried out feature gene subset selection. The classifiers considered are Fisher linear discrimination, Logit nonlinear discrimination, Mahal distance and Knearest neighbor classifier. We applied a threefold crossvalidation to assess the two-class discriminating ability of feature genes included in gene cores at the deepest level (core genes). At the same time, the same numbers of genes were sampled randomly from all genes to do the same work, and to assure randomness, the random sampling was repeated ten times. Results listed in Table 5 show that two-class discriminating ability of core genes is markedly higher than that of the randomly sampled genes, especially, when Fisher linear discrimination, Logit nonlinear discrimination and Mahal distance discrimination are used, the accuracy of core genes can reach around 90%.
Conclusion
Our approach reported in this paper extended our previously developed ensemble decision approach. Both approaches aim to mine disease-relevant genes for the classification of biological types. However, they are different. Firstly, our approaches analyze the multiple heterogeneous phenotypes with another discriminant index d with which selected subsets would distinguish positive and negative phenotypes in a highly unbalanced class distribution. Secondly, by the supervision of classifying the performance of some so-called 'redundant' genes we retrieved as many redundant genes as possible, which are very important in elucidating the complex genetic architecture of a complex disease. Finally, in addition to the single gene marker, significant function concepts found by mapping genes onto a gene function classifying frame Gene Ontology are analyzed, which avoids unnecessary loss of important genes during the microarray design, and improves the interpretability of the data mining results.
In our study, we proposed a method for the extraction of critical disease-relevant genes through multiple feature subsets, each being selected based on its classifying performance. By retrieving the 'redundant' genes, the majority of strongly relevant and partially relevant genes can be identified. Our findings support our speculation that retrieving feature genes is efficient for extracting 'redundant' genes. For example, gene SMRT, has two clones that have been both identified. By mapping these relevant genes onto GO, the molecular bridge of multiple phenotypes elucidating the disease mechanism is unraveled, which may provide valuable clues for the further research.
Feature genes and hierarchical gene cores identified by our method have achieved accuracy in the classification of multiple phenotypes. In the study, we performed external cross-validations. Using external classifiers we obtained an unbiased estimate of the classification performance of the deepest gene cores, and a high accuracy which shows gene cores definitely have discriminate ability of subtypes of lymphoma. In the future, genes in gene cores which lack function annotations need further investigations.
